project x bpc-157 BPC 157 in Australia: Benefits, side effects, risks and legality Project X BPC-157 High Dose
Description
CagriSema showed 22.7% at 68 weeks, but Novo Nordisk is running a direct head-to-head trial (NCT06131437) that will settle the comparison in a way indirect data cannot
They were both extremely knowledgeable and answered all my questions
Not the forum anecdotes or the marketing claims, but the peer-reviewed mechanisms and outcomes
Ideal for a range of system support at a far lower dose than is typically needed
Nutrients 2023;15:4960
